Home
| Databases
| WorldLII
| Search
| Feedback
Generic Top Level Domain Name (gTLD) Decisions |
Allergan Inc. v. Medbotox Inc.
Claim Number: FA0307000170639
Complainant is Allergan Inc., Irvine, CA (“Complainant”) represented by Martin A. Voet.
Respondent is Medbotox Inc.,
Richmond, BC, Canada (“Respondent”).
REGISTRAR
AND DISPUTED DOMAIN NAME
The
domain name at issue is <medbotox.com> registered with Tucows.
The
undersigned certifies that she has acted independently and impartially and that
to the best of her knowledge she has no known
conflict in serving as Panelist
in this proceeding. Hon. Carolyn Marks Johnson sits as Panelist.
Complainant
submitted a Complaint to the National Arbitration Forum (the "Forum")
electronically on July 22, 2003; the Forum
received a hard copy of the
Complaint on July 23, 2003.
On
July 23, 2003, Tucows confirmed by e-mail to the Forum that the domain name <medbotox.com>
is registered with Tucows and that Respondent is the current registrant of the
name. Tucows has verified that Respondent is bound
by the Tucows registration
agreement and has thereby agreed to resolve domain-name disputes brought by
third parties in accordance
with ICANN's Uniform Domain Name Dispute Resolution
Policy (the "Policy").
On
July 25, 2003, a Notification of Complaint and Commencement of Administrative
Proceeding (the "Commencement Notification"),
setting a deadline of
August 14, 2003, by which Respondent could file a Response to the Complaint,
was transmitted to Respondent
via e-mail, post and fax, to all entities and
persons listed on Respondent's registration as technical, administrative and
billing
contacts, and to postmaster@medbotox.com by e-mail.
Having
received no Response from Respondent, using the same contact details and
methods as were used for the Commencement Notification,
the Forum transmitted
to the parties a Notification of Respondent Default.
On
August 26, 2003, pursuant to Complainant's request to have the dispute decided
by a single-member Panel, the Forum appointed Hon.
Carolyn Marks Johnson as
Panelist.
Having
reviewed the communications records, the Administrative Panel (the
"Panel") finds that the Forum has discharged its
responsibility under
Paragraph 2(a) of the Rules for Uniform Domain Name Dispute Resolution Policy
(the "Rules") "to
employ reasonably available means calculated
to achieve actual notice to Respondent."
Therefore, the Panel may issue its decision based on the documents
submitted and in accordance with the ICANN Policy, ICANN Rules,
the Forum's
Supplemental Rules and any rules and principles of law that the Panel deems
applicable, without the benefit of any Response
from Respondent.
Complainant
requests that the domain name be transferred from Respondent to Complainant.
A. Complainant makes the following assertions:
1. The domain name registered by Respondent,
<medbotox.com>, is confusingly similar to Complainant’s BOTOX
mark.
2. Respondent has no rights or legitimate
interests in the <medbotox.com> domain name.
3. Respondent registered and used the <medbotox.com>
domain name in bad faith.
B. Respondent failed to submit a Response in
this proceeding.
Complainant
holds a number of trademark registrations with the United States Patent and
Trademark Office (“USPTO”) for the BOTOX mark,
including Reg. No. 1,692,384 (registered
on June 9, 1992) in relation to pharmaceutical preparations, namely, ophthalmic
muscle relaxants.
Complainant
marketed its pharmaceutical for the therapeutic treatment of neurological
disorders and muscle dystonias under the BOTOX
mark in the United States and
abroad. Recently Complainant began marketing this product for certain cosmetic
indications.
Respondent
registered the <medbotox.com> domain name on February 23, 2003.
Respondent is using the disputed domain name to divert Internet traffic to a
website that offers
a product that purports to therapeutically effect
involuntary movement disorders with a neuro-pathology. Respondent’s product
allegedly
also temporarily eliminates facial wrinkles.
Paragraph 15(a)
of the Rules instructs this Panel to "decide a complaint on the basis of
the statements and documents submitted
in accordance with the Policy, these
Rules and any rules and principles of law that it deems applicable."
In view of
Respondent's failure to submit a Response, the Panel shall decide this
administrative proceeding on the basis of Complainant's
undisputed
representations pursuant to paragraphs 5(e), 14(a) and 15(a) of the Rules and
will draw such inferences as the Panel considers
appropriate pursuant to
paragraph 14(b) of the Rules.
Paragraph 4(a)
of the Policy requires Complainant to prove each of the following three
elements to obtain an order that a domain name
should be cancelled or
transferred:
(1) the domain name registered by Respondent
is identical or confusingly similar to a trademark or service mark in which
Complainant has
rights; and
(2) Respondent has no rights or legitimate
interests in respect of the domain name; and
(3) the domain name has been registered and
is being used in bad faith.
Complainant
established in this proceeding that it has rights in the BOTOX mark through
registration with the USPTO. See Men’s Wearhouse, Inc. v. Wick, FA
117861 (Nat. Arb. Forum Sept. 16, 2002) (“Under U.S. trademark law, registered
marks hold a presumption that they are inherently
distinctive and have acquired
secondary meaning”).
The domain name
registered by Respondent, <medbotox.com>, is confusingly similar
to Complainant’s BOTOX mark because the disputed domain name incorporates
Complainant’s entire mark and merely
adds the prefix “med” to the mark. The
addition of letters such as “med” to the beginning of the mark does not
sufficiently differentiate
the domain name from the mark pursuant to Policy ¶
4(a)(i) because the mark remains the principal element of the domain name. See Kelson Physician Partners, Inc. v. Mason,
CPR003 (CPR 2000) (finding that <kelsonmd.com> is identical or
confusingly similar to Complainant’s federally registered service
mark,
“Kelson”); see also Am. Online,
Inc. v. Fu, D2000-1374 (WIPO Dec. 11, 2000) (finding that adding the
suffixes "502" and "520" to the ICQ trademark does
little
to reduce the potential for confusion).
Accordingly, the
Panel finds that Complainant has established Policy ¶ 4(a)(i).
Complainant
established that it has rights and legitimate interests in the mark and
asserted that Respondent has no such rights.
Respondent has not challenged the allegations in the Complaint. Under
these circumstances it is appropriate for the Panel to accept
all reasonable
allegations and inferences in the Complaint as true. See Bayerische Motoren
Werke AG v. Bavarian AG, FA110830 (Nat. Arb. Forum June 17, 2002) (finding
that in the absence of a Response the Panel is free to make inferences from
the
very failure to respond and assign greater weight to certain circumstances than
it might otherwise do); see also
Desotec N.V. v. Jacobi Carbons AB, D2000-1398 (WIPO Dec. 21, 2000) (finding
that failing to respond allows a presumption that Complainant’s allegations are
true unless
clearly contradicted by the evidence).
Moreover, due to
Respondent’s failure to answer the Complaint, the Panel presumes that
Respondent lacks rights to or legitimate interests
in the disputed domain name
in accord with Policy ¶ 4(a)(ii). See
Canadian Imperial Bank of Commerce v. D3M Virtual Reality Inc., AF-0336
(eResolution Sept. 23, 2000) (finding no rights or legitimate interests where
no such right or interest was immediately
apparent to the Panel and Respondent
did not come forward to suggest any right or interest it may have possessed); see
also Geocities v. Geociites.com,
D2000-0326 (WIPO June 19, 2000) (finding that Respondent has no rights or
legitimate interests in the domain name because Respondent
never submitted a
Response or provided the Panel with evidence to suggest otherwise).
Respondent is
using the <medbotox.com> domain name to market a product that
competes directly with Complainant’s products marketed under the BOTOX mark.
The use of a domain
name confusingly similar to a registered mark to offer a
product in competition with the mark holder’s products does not suggest
a bona
fide offering of goods or services pursuant to Policy ¶ 4(c)(i) or a legitimate
noncommercial or fair use pursuant to Policy
¶ 4(c)(iii). See Computerized
Sec. Sys., Inc. d/b/a SAFLOK v. Hu, FA 157321 (Nat. Arb. Forum June 23,
2003) (holding that Respondent’s appropriation of Complainant’s mark to market
products that
compete with Complainant’s goods does not constitute a bona fide
offering of goods and services); see also Clear Channel Communications, Inc.
v. Beaty Enters., FA 135008 (Nat. Arb. Forum Jan. 2, 2003) (finding that
Respondent, as a competitor of Complainant, had no rights or legitimate
interests
in a domain name that utilized Complainant’s mark for its competing
website).
Furthermore,
Respondent produced no proof and no evidence in the record indicates that
Respondent is commonly known by MEDBOTOX or
<medbotox.com>. Accordingly, the Panel finds that Respondent
has failed to show that Respondent has any rights to or legitimate interests in
the disputed
domain name under Policy ¶ 4(c)(ii). See Gallup Inc. v. Amish Country Store, FA
96209 (Nat. Arb. Forum Jan. 23, 2001) (finding that Respondent does not have
rights in a domain name when Respondent is not known
by the mark); see also
RMO, Inc. v. Burbridge, FA 96949 (Nat. Arb. Forum May 16, 2001) (interpreting
Policy ¶ 4(c)(ii) "to require a showing that one has been commonly known
by the domain name prior to registration of the domain name to prevail").
The Panel finds
that Complainant has established Policy ¶ 4(a)(ii).
Complainant
alleged that Respondent registered and used the domain name in bad faith.
Respondent is using a domain name confusingly
similar to Complainant’s mark to
offer goods in direct competition with Complainant’s goods. Respondent’s
registration and use of
the <medbotox.com> domain name
demonstrates bad faith registration and use because Respondent registered the
disputed domain name primarily for the
purpose of disrupting the business of a
competitor, which is evidence of bad faith registration and use with regard to
Policy ¶ 4(b)(iii).
See
EthnicGrocer.com, Inc. v. Unlimited Latin Flavors, Inc., FA 94385 (Nat.
Arb. Forum July 7, 2000) (finding that the minor degree of variation from
Complainant's marks suggests that Respondent,
Complainant’s competitor,
registered the names primarily for the purpose of disrupting Complainant's
business); see also S. Exposure v. S. Exposure, Inc., FA 94864 (Nat. Arb.
Forum July 18, 2000) (finding Respondent acted in bad faith by attracting
Internet users to a website that
competes with Complainant’s business).
Furthermore,
Respondent’s registration and subsequent use of the <medbotox.com>
domain name to offer Internet users goods that compete with goods under
Complainant’s BOTOX mark demonstrates Respondent’s bad faith
registration and
use of the disputed domain name because Respondent is capitalizing on the
likelihood of confusion between the domain
name and the mark, which evidences
bad faith registration and use under Policy ¶ 4(b)(iv). See Perot Sys. Corp. v. Perot.net, FA 95312
(Nat. Arb. Forum Aug. 29, 2000) (finding bad faith where the domain name in
question is obviously connected with Complainant’s
well-known marks, thus
creating a likelihood of confusion strictly for commercial gain); see also MathForum.com, LLC v. Huang, D2000-0743
(WIPO Aug. 17, 2000) (finding bad faith under Policy ¶ 4(b)(iv) where
Respondent linked <drmath.com>, which contains
Complainant’s Dr. Math
mark, to a website run by Respondent, creating confusion for Internet users
regarding the endorsement, sponsorship,
of affiliation of the website).
The Panel finds
that Policy ¶ 4(a)(iii) has been established.
Having
established all three elements required under the ICANN Policy, the Panel
concludes that relief shall be GRANTED.
Accordingly, it
is Ordered that the <medbotox.com> domain name be TRANSFERRED
from Respondent to Complainant.
Hon. Carolyn Marks Johnson, Panelist
Dated: September 9, 2003.
WorldLII:
Copyright Policy
|
Disclaimers
|
Privacy Policy
|
Feedback
URL: http://www.worldlii.org/int/other/GENDND/2003/896.html